High-level CD25 expression has been identified on CD34+/CD38− cells, suggesting that targeting CD25 might provide another avenue to complement TKI treatment to improve CML outcomes [49]. The gene discussed is IL2RA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.